Single User License: $5500
Member Price: FREE
Use code SUMMER at checkout for 50% OFF
Already a member? Login to access this report free.
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 through 2028.
Report Includes
- 34 data tables
- An overview of the global market for induced pluripotent stem cells (iPSCs)
- Analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by reprogramming method, method, application, derived tissue cell type, species, product function, end use, and geographic region
- Analysis of the market’s dynamics, including drivers, restraints and opportunities, and the regulatory environments impacting the market
- Assessment of R&D activity in the iPSC segment, as well as new developments and pipeline products
- Information on the latest research activities, emerging technologies, and clinical trials
- Market share analysis of the key companies and coverage of mergers & acquisitions, joint ventures, collaborations, and partnerships
- Profiles of the major players in the industry
Report Scope
This study focuses on the market side of iPSCs rather than the technical side. Different market segments for this emerging market are covered. For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types. Other cell types are comprised of astrocytes, fibroblasts, and hematopoietic and progenitor cells, among other substances. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications, and research publications in the field.
This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products that are broadly applicable to any stem cell type.
This report discusses key manufacturers, technologies, and factors influencing market demand, including the driving forces and limiting factors of the iPSC market’s growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2028. One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies; body-on-a-chip; and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
Detailed technologies such as those for generating iPSCs, differentiating iPSCs and controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under Good Manufacturing Practice (GMP) compliance or xeno-free conditions are excluded from the study. They are beyond the scope of this report.
The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW). The report will provide details with respect to induced pluripotent stem cells.
Report Synopsis
Report Metrics | Details | ||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Base year considered | 2022 | ||||||||||||||||||||||||||||||||||||||
Forecast period considered | 2023-2028 | ||||||||||||||||||||||||||||||||||||||
Base year market size | $3.1 billion | ||||||||||||||||||||||||||||||||||||||
Market size forecast | $5.2 billion | ||||||||||||||||||||||||||||||||||||||
Growth rate | CAGR of 9.1% from 2023 to 2028 | ||||||||||||||||||||||||||||||||||||||
Units considered | $ Millions | ||||||||||||||||||||||||||||||||||||||
Segments covered | By Reprogramming Method, Application, Method, Derived Tissue Cell Type, Species, Product Function, End Use, and Geographic Region | ||||||||||||||||||||||||||||||||||||||
Regions covered | The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW) | ||||||||||||||||||||||||||||||||||||||
Key Market Drivers |
|
||||||||||||||||||||||||||||||||||||||
Companies studied |
|
Frequently Asked Questions (FAQs)
Analyst Credentials
Shehanaz Pathan– Assistant Manager- Life Sciences Research
Shehanaz Pathan is an experienced professional with more than a decade of industry experience in research and analysis, specializing in healthcare. She has a wide range of experience in multiple domains, such as pharmaceuticals, biotechnology, medical devices, and healthcare IT. She designs research studies and provides end-to-end analysis to clients with real-time market insights and recommendations. Academically, Shehanaz holds a master’s degree in Marketing, as well as a bachelor’s degree in Microbiology.
Consulting Editor’s Credentials
Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.
Report Highlights
The global market for induced pluripotent stem cells should grow from $2.8 billion in 2021 to $4.4 billion by 2026, at compound annual growth rate (CAGR) of 9.3% for the period of 2021-2026.
Report Includes
- 43 tables
- An updated review of the global market for induced pluripotent stem cells (iPSC) within the industry
- Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of the market size and revenue forecast for the iPSCs market, and corresponding market share analysis by market segments such as application, reprogramming method, iPSCs generation method, product function and geography
- Highlights of emerging technology trends, market opportunities and deterrents estimating current and future demand of iPSC-related products and their derivatives for drug discovery
- Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
- Discussion of market dynamics that impact the growth of the market for iPSCs, clinical applications, market regulations, industry structure, and penetration of technologies within the biotech industry
- Insight into the segmentation of iPSC products, including iPSC research and clinical products, along with application-based segments such as academic research, drug development and regenerative medicine as well as iPSC-related contract services
- Number of global (+ the U.S.) patents and patent applications on induced pluripotent stem cells, and corresponding iPSC scientific publications during the period of 2008-October 2019
- Competitive landscape of the key manufacturers and suppliers in the iPSC market, their competitive environment and major growth strategies within the global market
- Descriptive company profiles of leading industry players, including Applied Biological Materials Inc., Bristol-Myers Squibb, Corning Inc., Merck KGaA and Thermo Fisher Scientific
Report Highlights
The global induced pluripotent stem cells (iPSC) market should reach $3.8 billion by 2024 from $2.4 billion in 2019 at a compound annual growth rate (CAGR) of 9.2% for the forecast period of 2019 to 2024.
Report Includes
- 59 tables
- An overview of the global market for induced pluripotent stem cells
- Analyses of global market trends with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
- Information on induced pluripotent stem cell research products, including various assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes
- Complete understanding of the key technologies adopted for induced pluripotent stem cell research
- Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth
- Profiles of major players in the industry, including Applied StemCell Inc., BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group Ltd., Promega Corp. and Thermo Fisher Scientific Inc.
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) reached $2.1 billion in 2016. The market should reach $3.6 billion in 2021, increasing at a compound annual growth rate (CAGR) of 11.6% from 2016 through 2021.
Report Includes
- An overview of the global market for induced pluripotent stem cells.
- Analyses of global market trends with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021.
- Information on induced pluripotent stem cell research products, defined as all research tools including but not limited to: induced pluripotent stem cells and various differentiated cells derived from induced pluripotent stem cells; various related assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes, and many others that can be applied for the specific purpose of executing induced pluripotent stem cell research.
- Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth.
- Profiles of major players in the industry.
Report Highlights
The global market for induced pluripotent stem cells (iPSCs) was estimated to total $853 million in 2012, and close to $1.2 billion in 2013, averaging 40% growth. The market is expected to reach $2.9 billion in 2018, an estimated compound annual growth rate (CAGR) of 19.7% for the five-year period 2013 to 2018.
Report Includes
- An overview of the global market for induced pluripotent stem cells.
- Analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
- Information on induced pluripotent stem cell research products, defined as all research tools including but not limited to: induced pluripotent stem cells and various differentiated cells derived from induced pluripotent stem cells, various related assays and kits, culture media and medium components such as serum, growth factors and inhibitors, antibodies, enzymes, and many others that can be applied for the specific purpose of executing induced pluripotent stem cell research.
- Discussion of important manufacturers, technologies, and factors influencing market demand such as the driving forces and limiting factors of induced pluripotent stem cell market growth.
Related Reports
Global Automated and Closed Cell Therapy Market
The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.
Cell Therapy Biomanufacturing: Global Markets
The global market for cell therapy biomanufacturing is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2024 to 2029.
Global Market for Stem Cells
The global stem cell market reached $32.1 billion in 2022 and should reach $65.6 billion by 2027, with a compound annual growth rate (CAGR) of 15.3% during the forecast period of 2022-2027.
Cell-Based Assays: Technologies and Global Markets
The global cell-based assays market should reach $47.3 billion by 2027 from $29.2 billion in 2022 at a compound annual growth rate (CAGR) of 10.2% for the forecast period of 2022 to 2027.
Recent Reports
Synthetic Biology: Global Markets
The global market for synthetic biology products was valued at $15.4 billion in 2023. The market is projected to grow from $19.3 billion in 2024 to $61.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 26.1% from 2024 through 2029.
Gene Editing Therapeutics Market
The report provides an overview of current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also include company profiles of key players, featuring detailed information regarding each company’s business segments, financials, product portfolios and recent developments.
Global Live Cell Imaging Market
The global market for live cell imaging is expected to grow from $2.9 billion in 2024 and is projected to reach $4.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 8.4% during the forecast period of 2024 to 2029.
Global Single-cell Technologies Market
The global market for single-cell technologies is estimated to increase from $3.6 billion in 2023 to reach $9.2 billion by 2029, at a compound annual growth rate (CAGR) of 17.1% from 2024 through 2029.
Artificial Intelligence (AI) in Life Sciences Market
The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
Top Trending Reports
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
Carbon Credits Market: Global Outlook
This report provides an up-to-date analysis of current and future markets for carbon credits and the carbon offsets industry. It presents a thorough and up-to-date global assessment of the market and business of carbon credits. The report also includes a competitive landscape, ESG analysis, and detailed company profiles of leading market players.
Wearable Medical Devices: Technologies and Global Markets
The global market for wearable medical devices was valued at $35.6 billion in 2023. This market is estimated to grow from $45.0 billion in 2024 to $151.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.5% from 2024 through 2029.
Biodegradable Polymers: Global Markets and Technologies
The global market volumes of biodegradable polymers is expected to grow from 1,286.0 kilotons in 2023 and is projected to reach 4,140.0 kilotons by the end of 2028, at a compound annual growth rate (CAGR) of 26.3% during the forecast period of 2023 to 2028.
Plastics Recycling: Global Markets
The global market for plastic recycling is expected to grow from $42.4 billion in 2024 to $57.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More